BCM
CSTL icon

Bridgeway Capital Management’s Castle Biosciences CSTL Stock Holding History

Bridgeway Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.28M Sell
221,338
-33,846
-13% -$754K 0.09% 295
2026
Q1 		$6.26M Buy
255,184
+8,264
+3% +$271K 0.13% 231
2025
Q4 		$9.61M Buy
246,920
+69,740
+39% +$2.25M 0.2% 147
2025
Q3 		$4.03M Buy
177,180
+136,430
+335% +$2.77M 0.09% 314
2025
Q2 		$832K Buy
+40,750
New +$754K 0.02% 685

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management's CSTL Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Castle Biosciences (CSTL) stake by 13% in Q2 2026, selling an estimated $754K and leaving 221,338 shares worth $5.28M. The position accounts for 0.09% of the portfolio, ranked #295.

Bridgeway Capital Management first reported a position in CSTL in Q2 2025 and has held it in 5 quarters since. The position peaked at $9.61M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Bridgeway Capital Management held 221,338 shares of Castle Biosciences worth $5.28M as of Q2 2026.
  • Bridgeway Capital Management sold 33,846 Castle Biosciences shares in Q2 2026, an estimated $754K.
  • Castle Biosciences made up 0.09% of Bridgeway Capital Management's portfolio in Q2 2026, its #295 holding.
  • Bridgeway Capital Management first reported a position in Castle Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Castle Biosciences position peaked at $9.61M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.